BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayar MA, Antoun S, Lanoy E. Statistical approaches for evaluating body composition markers in clinical cancer research. Expert Rev Anticancer Ther 2017;17:311-8. [PMID: 28277100 DOI: 10.1080/14737140.2017.1298446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Marquardt JP, Roeland EJ, Van Seventer EE, Best TD, Horick NK, Nipp RD, Fintelmann FJ. Percentile-based averaging and skeletal muscle gauge improve body composition analysis: validation at multiple vertebral levels. J Cachexia Sarcopenia Muscle 2021. [PMID: 34729952 DOI: 10.1002/jcsm.12848] [Reference Citation Analysis]
2 Kubiak CA, Ranganathan K, Matusko N, Jacobson JA, Wang SC, Park PK, Levi BL. Computed Tomography Evidence of Psoas Muscle Atrophy Without Concomitant Tendon Wasting in Early Sepsis. J Surg Res 2019;234:210-6. [PMID: 30527476 DOI: 10.1016/j.jss.2018.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Benavides-Rodríguez L, García-Hermoso A, Rodrigues-Bezerra D, Izquierdo M, Correa-Bautista JE, Ramírez-Vélez R. Relationship between Handgrip Strength and Muscle Mass in Female Survivors of Breast Cancer: A Mediation Analysis. Nutrients 2017;9:E695. [PMID: 28677652 DOI: 10.3390/nu9070695] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
4 Sierzega M, Chrzan R, Wiktorowicz M, Kolodziejczyk P, Richter P. Prognostic and predictive implications of sarcopenia in Western patients undergoing gastric resections for carcinoma of the stomach. J Surg Oncol 2019;120:473-82. [PMID: 31124178 DOI: 10.1002/jso.25509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
5 Antoun S, Bayar MA, Dyevre V, Lanoy E, Smolenschi C, Ducreux M. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. BMC Cancer 2019;19:847. [PMID: 31462288 DOI: 10.1186/s12885-019-6086-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
6 Kurk SA, Stellato RK, Peeters PHM, Dorresteijn B, Jourdan M, Oskam MJ, Punt CJA, Koopman M, May AM. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. Am J Clin Nutr. 2019;110:1395-1403. [PMID: 31515555 DOI: 10.1093/ajcn/nqz209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Creemers GM, Erdkamp FLG, de Jongh FE, Kint PAM, Poppema BJ, Radema SA, Simkens LHJ, Tanis BC, Tjin-A-Ton MLR, Van Der Velden A, Punt CJA, Koopman M, May AM. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. Cancer Med. 2020;9:1033-1043. [PMID: 31850687 DOI: 10.1002/cam4.2787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]